Levopalm-MA Tablet SR is a sustained-release formulation combining Ambroxol (75 mg), Levocetirizine (5 mg), and Montelukast (10 mg), designed for the comprehensive management of respiratory conditions characterized by cough, allergic rhinitis, and bronchial asthma. Ambroxol acts as a potent mucolytic agent, facilitating the breakdown and clearance of mucus in the respiratory tract, thereby improving airway patency and easing expectoration. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, effectively reducing symptoms of allergic rhinitis such as sneezing, nasal congestion, and itching. Montelukast, a leukotriene receptor antagonist, prevents bronchoconstriction and inflammation by blocking leukotriene D4 at the cysteinyl leukotriene receptor, making it beneficial in the prophylaxis and chronic treatment of asthma and allergic rhinitis. The sustained-release mechanism ensures prolonged therapeutic effects, enhancing patient compliance by reducing dosing frequency. Levopalm-MA is indicated for patients requiring simultaneous management of mucus hypersecretion, allergic symptoms, and bronchial hyperresponsiveness. It should be used under medical supervision, with caution advised in patients with hepatic or renal impairment. Common adverse effects may include headache, gastrointestinal discomfort, and mild sedation. This combination therapy offers a multifaceted approach to respiratory care, optimizing symptom control and improving quality of life.